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(26.9%). Overall, MPRs were 0.58 for long-acting beta-agonists
(LABA); 0.61 for ipratropium+short-acting beta-agonist; 0.63
for ipratropium; 0.63 for inhaled corticosteroids (ICS); and 0.90
for theophylline (THEO). There were similar results in stratiﬁed
analyses by disease group with lowest MPRs for LABA and
highest for THEO. For ICS users, factors associated with MPRs
>= 0.75 were: higher proportion of prescriptions through mail
order, Caucasians, and ED visit or hospitalization in the baseline
period. For LABA users, in addition to the factors for ICS users,
specialist provider visits were associated with high MPRs. CON-
CLUSIONS: Patients had higher levels of adherence for oral
medications than for inhaled medications. Higher adherence
rates were associated with serious events and greater use of mail
order. Thus, route of administration, disease and health system
factors all appear to inﬂuence adherence to chronic respiratory
medications.
PRS10
PREDICTORS OF DRUG PERSISTENCY FOR ASTHMA AND
COPD PATIENTS
Lipskiy N, Hess G, Fruchtl B
Surveillance Data Inc, Plymouth Meeting, PA, USA
OBJECTIVE: This study examines the predictors of patient per-
sistency for major drug categories related to the treatment of
Asthma and COPD. METHODS: The study design was retro-
spective covering the 12-month, longitudinal period (October
2003–September 2004). It included analysis of electronic
CMS1500 claims for 26,152 unique patients (HIPAA compli-
ant). Patients’ medication was assessed through NCPDP elec-
tronic claims utilizing NDC codes and drug classes. Treatment
persistency was identiﬁed and compared across drugs in each
disease group. Analysis included calculations of descriptive sta-
tistics and regression modeling. RESULTS: On average, COPD
patients are more persistent then asthma patients. In particular,
the persistency of COPD patients taking Advair, Combivent,
Flovent and Pulmicort was higher then those patients diagnosed
with asthma, respectively by 13.5%, 34.3%, 25.8% and 34.6%
(P < 0.05). The age of patients is one of the most important pre-
dictors of a patients’ persistency. For example, the likelihood of
reﬁlling a long-acting bronchodilator (LABA) prescription for
asthma in patients age 18 years and older is 1.51 times higher
(p < 0.05) than for those patients who are in the age category
17 years and younger. For both, asthma and COPD, there is a
strong relationship between therapeutic class of drugs and per-
sistency. The highest persistency of asthma patients was identi-
ﬁed for those who use xanthines, and the lowest for those who
take oral beta-blockers (1.89 times difference, P < 0.05). COPD
patients were more persistent in their use of xanthines and had
their lowest persistency on inhaled corticosteroids (1.66 times
difference, P < 0.05). Logistic regression models were created to
quantify the relationship between annual average lengths of
treatment and predictors. CONCLUSIONS: There is a signiﬁ-
cant difference between drug persistency for patients with
asthma and COPD even when controlling for the same medica-
tion. Adjusted for diagnosis, the major predictors of patient 
persistency appeared to be patient’s age and therapeutic drug 
category.
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OBJECTIVE: To establish the need to include designated 
community (private) pharmacies/pharmacists in the Lagos State
DOTS programme for effective control of Tuberculosis.
METHOD: A cross sectional descriptive study involving the 
use of semi structured questionnaires administered to a random
sample of an estimated population(150) of community pharma-
cists in Lagos State of Nigeria. Data was analysed by use of SPSS
12. RESULTS: The results show that: 86.8% of respondents
stocked anti-TB drugs; 67.2% of them had dispensed these drugs
at least within the immediate past one month preceding survey;
19.3% of them were patronised daily and 43.3% dispensed
without a doctors prescription. 63.7% of respondents did not
acknowledge that TB drugs were given to patients free of charge
anywhere, 43.4% did not know about DOTS; 89.2% were of
the opinion that community pharmacies would help increase TB
control coverage, 68.1% would accept to render DOTS services
in their pharmacies out of which 15.5% would do that at no
costs. 80.9% of respondents claimed that a pharmacist is on 
duty in their pharmacies throughout open hours; however 
most were not seen until after several visits. 1.4% of the phar-
macists were of the opinion that TB is incurable while 8.3% 
said TB runs in families, however 75.8% reported that most 
HIV patients present with TB co-infection. CONCLUSION:
Designated community pharmacies that meet basic ethical
requirements with regards to environment, facilities, location
and personnel should be accredited to render DOTS services for
effective and efﬁcient grass root TB control, especially in places
like Nigeria where TB is on the increase as a result of HIV 
pandemic. This will improve proper monitoring and patients
compliance by reducing travel time, cost and risk of travel to
clinics, social stigmatisation, waiting time, and generally reduce
the real cost of treatment for patients, with an assured wider 
coverage.
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INTRODUCTION: This study identiﬁes important risk factors,
race and predictors of heart failure (HF) in a chronic obstructive
pulmonary disease (COPD) Medicaid population, to help inform
plans and better target interventions for COPD disease manage-
ment. METHODS: A retrospective analysis was performed for
all medical claims of Medicaid COPD patients, between January
1, 2001-December, 31, 2003. COPD patients were included if
they had at least one claim with ICD-9 codes 491.xx, 4922.xx,
or 496.xx, in the primary, secondary or tertiary diagnosis. We
used multivariate logistic regression models to evaluate associa-
tions between heart failure and race, adjusting for age, gender,
cardiovascular diseases and risk factors. RESULTS: Total of
13,924 COPD patients, mean age 42. African Americans (OR =
1.25 p = 0.0001 CI 1.12–1.40) were more likely to have HF than
others during their follow up, even after adjusting for age, gender
and clinical risk factors. Patients older than 60 (OR = 5.13 p <
0.0001 CI 4.16–6.32) and those between 40 and 60 (OR = 3.34
p < 0.0001 CI 2.75–4.05) were more likely to have HF than those
younger than 40. Hypertension (OR = 2.30 p < 0.0001 CI
2.02–2.61), diabetes (OR = 2.16 p < 0.0001 CI 1.93–2.42),
obesity (OR = 2.18 p < 0.0001 CI 1.91–2.48), acute myocardial
infarction (OR = 3.09 p < 0.0001 CI 2.56–3.73) and cardiomy-
opathy (OR = 15.76 p < 0.0001 CI 12.95–19.18) were also sig-
niﬁcant predictors of heart failure. Gender and urban residence
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were not signiﬁcant in the model. CONCLUSIONS: Medicaid
patients, with COPD, who are African American, older than 40,
with a diagnosis of hypertension, obesity, diabetes, cardiomy-
opathy or myocardial infarction are at signiﬁcantly higher risk
for heart failure. Managed care plans may need to consider those
risk factors in Medicaid patients with COPD.
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HEALTH CARE EXPENDITURE AND UTILIZATION FOR
PATIENTS WITH CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE
Nurmagambetov T,Atherly A,Williams S, Redd S
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OBJECTIVE: This study estimates inpatient, outpatient, and
prescription drugs expenditures and health care utilization for
patients with Chronic Obstructive Pulmonary Disease (COPD).
METHODS: Inpatient and outpatient claims with primary diag-
nosis of COPD-deﬁning diseases (ICD-9 codes 491**, 492**,
496**) from 1998–2002 were extracted from Medstat Mar-
ketscan database and then matched to prescription drug expen-
ditures using unique identiﬁers. Regression models controlled for
age, gender, employment status, health plan type and other vari-
ables. All regression factors mentioned below were signiﬁcant
with p < 0.01. RESULTS: Average per patient annual expendi-
tures was $7874–$11,412 for inpatient service depending on 
the type of health plan; $154–$238 for outpatient visits; and
$85–$151 for prescription drugs. Results also indicated that
gender, age, health care plan type, the region where patient lived
and the patient’s industry type all signiﬁcantly affected health
care expenditures and utilization for COPD care. For example,
women were less likely to be hospitalized or receive outpatient
care, but were more likely to ﬁll COPD-related prescription
drugs. Patients in plans requiring a primary care physician 
referral to receive specialty care (PCP plans) were less likely to
be hospitalized, made fewer outpatient visits and ﬁlled fewer
COPD-related prescriptions. Overall, inpatient expenditures
were 1.2% higher for men and 18% lower for patients enrolled
in PCP plans. Outpatient expenditures were about 3% higher for
men and about 1.7% higher for patients in PCP plans. Prescrip-
tion medication expenditures were about 2% higher for men and
about 19% lower for patients in PCP plans. In all regressions,
older patients had higher expenditures. CONCLUSION: There
is a substantial economic burden associated with COPD which
can potentially be reduced signiﬁcantly by enrolling patient in
PCP plans. Further research is needed to examine why men with
COPD use more health care than women and to assess the
quality of care provided by PCP plans.
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OBJECTIVE: To conduct a beneﬁt-risk assessment comparing
telithromycin with other commonly prescribed therapies for 
the treatment of community-acquired pneumonia (CAP).
METHODS: We developed a model to quantify the beneﬁts and
risks of telithromycin versus other common therapies for CAP
in terms of quality-adjusted days (QAD) gained. A typical 
65-year-old patient was assumed to receive amoxicillin, clar-
ithromycin, or telithromycin for the treatment of acute CAP.
Drug efﬁcacy, drug resistance, adverse event (AE) rates and
sequelae, and utility decrements associated with CAP and AEs
were estimated from published clinical trials and other secondary
sources. Beneﬁts of telithromycin versus other therapies were
assessed by estimating the gain in QAD due to successful treat-
ment of CAP. Risks were assessed by estimating the QAD 
lost due to treatment-related AEs (liver toxicity, prolonged QT
interval, diarrhea, and blurry vision) and their sequelae. The net
beneﬁt of telithromycin was calculated by summing expected
beneﬁts and risks over the 21-day period after treatment initia-
tion (including lifetime QAD lost due to death and chronic 
conditions). We used a second-order Monte Carlo simulation 
to evaluate the effect of uncertainty in key model parameters on
our ﬁndings. RESULTS: Patients treated with telithromycin
versus amoxicillin are expected to gain 31.01 QAD due to suc-
cessful treatment of CAP and 0.26 QAD due to AEs. Versus clar-
ithromycin, telithromycin patients lose 0.01 QAD to AEs;
however, the net beneﬁt is a gain of 13.09 QAD. Probabilistic
sensitivity analyses showed telithromycin to be at least as bene-
ﬁcial as amoxicillin and clarithromycin in 85% and 68% of
10,000 iterations, respectively. CONCLUSIONS: Telithromycin
demonstrated a net beneﬁt in terms of QAD gained versus both
amoxicillin and clarithromycin despite slightly higher risks due
to AEs than clarithromycin. In general, QAD lost due to AEs
were negligible compared to the potential beneﬁts from success-
ful treatment of CAP with telithromycin.
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OBJECTIVES: Cost-effectiveness modeling in COPD is often
problematic because the utilization data is usually derived from
participants in randomized clinical trials, who may not be very
representative of patients treated in the general population. We
used the administrative data of a large cohort of COPD patients
treated by one managed care system to see whether exacerbation
events could be predicted with sufﬁcient accuracy to be used in
cost modeling. METHODS: COPD patients under usual care
who were continuously enrolled in the Lovelace Health Plan for
selected, seasonal 6-month blocks during the study’s observation
period (September 1, 2000 to August 31, 2003) were identiﬁed
using administrative data and a cross-sectional-pooling design
(N = 2850). Subsequent exacerbation events, deﬁned as hospital
admissions or outpatient encounters with a primary respiratory
diagnosis, were captured from the database. Logistic regression
models were then developed to identify factors associated with
exacerbations. RESULTS: Approximately 46% of the cohort 
had one or more exacerbations during the observation period.
Factors signiﬁcantly associated with an exacerbation (p < 0.05)
included age, the number of pulmonary and non-pulmonary out-
patient encounters, the total number of prescription ﬁlls, having
one or more serious comorbidities, ever having an additional
diagnosis of asthma, the season of the prior 6 month period as
well as having had an exacerbation as well as many two-way
interaction terms. The model was able to predict the status of
patients with a good degree of accuracy (69% concordant, 30%
discordant, 1% tied). CONCLUSIONS: COPD exacerbation
events can be reliably predicted from the utilization data com-
monly found in health system administrative databases. The pre-
dicted probabilities from these models can be used to estimate
transition probabilities in Markov and similar cost-effectiveness
models.
